Neuromyelitis optica spectrum disorders: long-term safety and efficacy of rituximab in Caucasian patients
- 21 July 2015
- journal article
- research article
- Published by SAGE Publications in Multiple Sclerosis Journal
- Vol. 22 (4), 511-519
- https://doi.org/10.1177/1352458515594042
Abstract
Subscription and open access journals from SAGE Publishing, the world's leading independent academic publisher.Keywords
This publication has 31 references indexed in Scilit:
- Allogeneic hematopoietic stem cell transplantation for neuromyelitis opticaAnnals of Neurology, 2014
- Prognostic factors and disease course in aquaporin-4 antibody-positive patients with neuromyelitis optica spectrum disorder from the United Kingdom and JapanBrain, 2012
- Neuromyelitis optica: Concepts in evolutionJournal of Neuroimmunology, 2011
- EFNS guidelines on diagnosis and management of neuromyelitis opticaEuropean Journal of Neurology, 2010
- Prevalence of neuromyelitis optica spectrum disorder and phenotype distributionZeitschrift für Neurologie, 2009
- B cells as therapeutic targets in autoimmune neurological disordersNature Clinical Practice Neurology, 2008
- The spectrum of neuromyelitis opticaPublished by Elsevier ,2007
- Revised diagnostic criteria for neuromyelitis opticaNeurology, 2006
- IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channelThe Journal of Experimental Medicine, 2005
- A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosisThe Lancet, 2004